A dog whose major clinical signs suggested a coagulopathy, is described. The dog had a history of bleeding episodes and had a severe regenerative anaemia. By using specific factor assays, the coagulopathy was found to be due to a consumptive intravascular process that resembled chronic disseminated intravascular coagulation. Subsequent investigations identified Angiostrongylus vasorum as the cause.

No abstract

The records of 15 horses with pemphigus foliaceus diagnosed on the basis of their history, clinical signs, histopathology and the exclusion of differential diagnoses were evaluated with respect to the age of onset, the clinical signs and the diagnostic tests used. There was no apparent breed predisposition. The horses' mean age was nine years, with a range from three months to 25.5 years, three were foals up to six months old and eight were nine years old or older. The most frequent lesions were scaling in 11, crusting in 10 and alopecia in 10, and they appeared most commonly on the face, neck and trunk, in 10 horses for each of these sites. The extremities were involved in nine of the horses, pruritus occurred in seven, and four of the horses had pustules. The clinical signs mostly corresponded with those described in previous reports, but signs of pain were not a prominent feature. Acantholytic cells were identified cytologically in four of six of the horses.

Atopic dermatitis has a strong genetic component, and breeding of dogs with clinical signs of atopic dermatitis should be discouraged.

A case of prolapsed intervertebral disc at C5–6 is described in an adult cat with a history of quadriparesis and two episodes of quadriplegia in a two year period. Plain radiographs showed no abnormality, there was no narrowing of the intervertebral space, but the protrusion was detected by myelography. Severe degeneration was found in the spinal cord.

This study evaluated PYM00217, a proprietary blend of plant extracts, in the management of canine atopic dermatitis (AD). One hundred and twenty dogs were diagnosed with perennial AD on the basis of history, clinical signs, a positive test for perennial allergens and elimination of other dermatoses. Exclusion criteria included antimicrobials within 7 days, antihistamines within 14 days, oral/topical glucocorticoids or ciclosporin within 28 days, and parenteral glucocorticoids, essential fatty acids or immunotherapy within 56 days. Flea control, shampoos and ear cleaners were permitted. Dogs with a minimum canine atopic dermatitis extent and severity index (CADESI) of 25 were randomly allocated to receive PYM00217 (100, 200 or 400 mg kg-1 day-1) or placebo for 12 weeks. The mean reductions in CADESI (intention-to-treat population) were 3.9% (placebo; n=29), 4.4% (100 mg kg-1 day-1; n=30), 23.4% (200 mg kg-1 day-1; n=29) and 8.5% (400 mg kg-1 day-1; n=29). The reduction in the 200 mg kg-1 day-1 group was significant (P<0.01). For dogs with a baseline CADESI>or=50, the mean changes were +10.6% (placebo; n=12), +0.6% (100 mg kg-1 day-1; n=14), -29.3% (200 mg kg-1 day-1; n=14) and -3.4% (400 mg kg-1 day-1; n=15). The 200 mg kg-1 day-1 dose was significantly more effective than placebo (P=0.038). No serious adverse effects were reported. Minor adverse effects seen in 10% (placebo and 100 mg kg-1 day-1), 24% (200 mg kg-1 day-1) and 42% (400 mg kg-1 day-1) of cases were mainly minor gastrointestinal disorders and only five cases required cessation of dosing. Two dogs (one in each of the 100 mg kg-1 day-1 and 200 mg kg-1 day-1 groups) refused to eat the medicated food. In conclusion, PYM00217 at 200 mg kg-1 appears to be an effective, palatable and well-tolerated treatment for canine AD.

Résumé— Les commémoratifs, les symptômes, l'histologie et la réponse au traitement d'un cheval de 15 ans atteint de lymphome cutané sont décrits. La jument présente de multiples nodules cutanés depuis 11 ans. Un diagnostic de lymphome cutané est poséà l'examen histologique de biopsies réalisées 2 fois à 4 ans d'intervalle. Des marquages immunihistochimiques identifient ces cellules comme appartenant à la lignée T. Ceci est la première description du marquage immunophénotypique d'un lymphome cutané chez le cheval. La jument a été traitée par des glucorticoïdes intralésionnels et des progestagènes oraux ce qui a entrainé une régression complète des nodules. Resumen— Describimos la historia clinica y los hallazgos clinicos e histológicos de un caballo de 15 años con un linfoma cutáneo. La yegua tenia una historia clinica de multiples nédules cutáneos en los últimos 11 años. Se diagnosticó un linfoma cutáneo mediante estudio histológico de dos biosias tomadas con unos cuatro años de separación. Tinciones inmunohistoquimicas ulteriores identificaron la linea celular de ünfocitos T. Este es el primer estudio que caracteriza el linfoma equino a nivel inmunofenotipico. La yegua fue tratada con glucocorticoides intralesionales y progestágenos orales, lo que resultó en curación total de los nódulos. Abstract— The history, clinical and histological features and response to treatment of a 15‐year‐old horse with cutaneous lymphoma are described. The mare had an 11 year history of multiple cutaneous nodules. A diagnosis of cutaneous lymphoma was made on histological examination of biopsy material taken on two separate occasions some 4 years apart. Subsequent immunohistochemical staining identified the cell lineage as T‐lymphocytes. This is the first report of immunophenotypic characterisation of cutaneous lymphoma in the horse. The horse was treated with intralesional glucocorticoids and oral progestins, and complete resolution of the nodules resulted.

Lateral reaching to the unaffected side early after stroke revealed a different pattern than normal and patients reached less far and moved at a slower speed. Specific training strategies to improve reaching are needed.